uniQure (QURE) Cash from Financing Activities (2016 - 2026)
uniQure's (QURE) quarterly Cash from Financing Activities came in at $550000.0 in Q1 2026, down 99.32% year-on-year from $80.7 million in Q1 2025, and down 77.54% quarter-over-quarter from $2.4 million in Q4 2025.
uniQure (QURE) Cash from Financing Activities (2016 - 2026) Analysis & Trends
uniQure's Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $550000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 99.32% year-over-year to $550000.0 in Q1 2026; TTM through Mar 2026 was $335.3 million, a 1482.99% increase from a year earlier, with the FY2025 full-year figure at $415.4 million, up 798.31% from the prior year.
- Cash from Financing Activities slipped to $550000.0 in Q1 2026 per QURE's latest filing, from $2.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $370.1 million in Q2 2023 and bottomed at -$53.0 million in Q3 2024.
- The 5-year median for Cash from Financing Activities is $301000.0 (2022), against an average of $48.0 million.
- Across the five-year window, Cash from Financing Activities jumped 638067.24% in 2023 and sank 14267.39% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $601000.0 in 2022, then slumped by 92.35% to $46000.0 in 2023, then sank by 14267.39% to -$6.5 million in 2024, then surged by 137.58% to $2.4 million in 2025, then slumped by 77.54% to $550000.0 in 2026.
- Per Business Quant, the three latest QURE Cash from Financing Activities figures stand at $550000.0 (Q1 2026), $2.4 million (Q4 2025), and $332.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | uniQure | 2.47 Bn | 2.47 Bn | 3.34 Mn | 550,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 550,000.00 |
| Mar 31, 2026 | 550,000.00 |
| Dec 31, 2025 | 2.45 Mn |
| Dec 31, 2025 | 2.45 Mn |
| Sep 30, 2025 | 332.24 Mn |
| Sep 30, 2025 | 332.24 Mn |
| Jun 30, 2025 | 44,000.00 |
| Jun 30, 2025 | 44,000.00 |
| Mar 31, 2025 | 80.67 Mn |
| Mar 31, 2025 | 80.67 Mn |
| Dec 31, 2024 | -6.52 Mn |
| Dec 31, 2024 | -6.52 Mn |
| Sep 30, 2024 | -53.02 Mn |
| Sep 30, 2024 | -53.02 Mn |
| Dec 31, 2023 | 46,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | -7.59 Mn |
| Sep 30, 2023 | -7.59 Mn |
| Jun 30, 2023 | 370.14 Mn |
| Jun 30, 2023 | 370.14 Mn |